Lirimilast
Modify Date: 2024-01-11 00:24:55
Lirimilast structure
|
Common Name | Lirimilast | ||
|---|---|---|---|---|
| CAS Number | 329306-27-6 | Molecular Weight | 443.25800 | |
| Density | 1.619g/cm3 | Boiling Point | 663.2ºC at 760 mmHg | |
| Molecular Formula | C17H12Cl2N2O6S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 354.9ºC | |
Use of LirimilastLirimilast (BAY 19-8004) is a potent, selective and orally active phosphodiesterase-4 (PDE4) inhibitor with an IC50 value of 49 nM. Lirimilast can be used for the treatment of asthma or chronic obstructive pulmonary disease (COPD). Lirimilast has potently anti-inflammatory properties[1][2]. |
| Name | [3-(carbamoylamino)-2-(2,4-dichlorobenzoyl)-1-benzofuran-6-yl] methanesulfonate |
|---|---|
| Synonym | More Synonyms |
| Description | Lirimilast (BAY 19-8004) is a potent, selective and orally active phosphodiesterase-4 (PDE4) inhibitor with an IC50 value of 49 nM. Lirimilast can be used for the treatment of asthma or chronic obstructive pulmonary disease (COPD). Lirimilast has potently anti-inflammatory properties[1][2]. |
|---|---|
| Related Catalog | |
| Target |
PDE4:42 nM (IC50) |
| In Vitro | In PDE4 assays Lirimilast (BAY 19-8004) is reported to be 5-fold more potent than Cilomilast and equipotent with CDP-840 using freshly prepared PDE4 from human PMNL[1]. |
| In Vivo | Since Lirimilast (BAY 19-8004) is orally active in the guinea-pig at 3 mg/kg and, more critically, in primates at 0.1 mg/kg/day it appears to have a good therapeutic ratio. In addition Lirimilast is found to be 3-fold more potent than Cilomilast when compared in a rat model of lung neutrophilic inflammation[2]. |
| References |
| Density | 1.619g/cm3 |
|---|---|
| Boiling Point | 663.2ºC at 760 mmHg |
| Molecular Formula | C17H12Cl2N2O6S |
| Molecular Weight | 443.25800 |
| Flash Point | 354.9ºC |
| Exact Mass | 441.97900 |
| PSA | 138.07000 |
| LogP | 5.46720 |
| Index of Refraction | 1.677 |
| Lirimilast |
| pumafentrine |
| UNII-GDK3KY5FCU |
| BAY-19-8004 |